Pharmacogenetics and adverse drug reactions

Lancet

Volumn 356, Issue 9242, 2000, Pages 1667-1671

  Meyer, Urs A ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; AMONAFIDE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE; CYTOCHROME P450; DIAZEPAM; DIGOXIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; GLIPIZIDE; HYDRALAZINE; IRINOTECAN; ISONIAZID; LOSARTAN; MERCAPTOPURINE; NEUROLEPTIC AGENT; OMEPRAZOLE; OPIATE DERIVATIVE; PHENYTOIN; PROCAINAMIDE; SULFONAMIDE; SUXAMETHONIUM; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

ADVERSE DRUG REACTION; ALLELE; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; DIARRHEA; DNA POLYMORPHISM; DRUG EFFICACY; DRUG METABOLISM; DRUG TARGETING; DRUG TRANSPORT; GENE MUTATION; GENOTYPE; HUMAN; HYPERSENSITIVITY; MULTIDRUG RESISTANCE; NEUROTOXICITY; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; TARDIVE DYSKINESIA;

EID: 0034638766     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)03167-6     Document Type: Article

References (29)

1. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
2. Genotype or phenotype: The definition of a pharmacogenetic polymorphism
3. Drugs in special patient groups: Clinical importance of genomics in drug effects
4. Polymorphic human cytochrome P450 enzymes; An opportunity for individualized drug treatment
5. Pharmacogenomics: Translating functional genomics into rational therapeutics
6. Pharmacogenetics and future drug development and delivery
7. Molecular mechanisms of genetic polymorphisms of drug metabolism
8. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
9. Cytochrome P4502C9; An enzyme of major importance in human drug metabolism
10. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele
11. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans
12. Pharmacogenetics and cancer chemotherapy
13. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism
14. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6
15. The essence of SNPs
16. Hypothesis: Comparison of inter- and intra-individual variations can substitute for twin studies in drug research
17. Pharmacogenetics of antidepressants: Clinical aspects
18. 10-hydroxylation of nortiptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes
19. The pharmacogenetics of codeine hypoalgesia
20. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans
21. Extension of a pilot study: Impact of the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness
22. Methylation pharmacogenetics: Catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methytransferase
23. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
24. The role of innovation in drug development
25. The pharmacogenetics of beta2-adrenergic receptors: Relevance to asthma
26. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonyurea receptor gene
27. Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management parts I and II*
28. Angiotensin-converting enzyme gene I/D polymorphism and renal disease
29. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response